GPL receives ANDA approval for Colesevelam Hydrochloride for Oral Suspension General Announcement Filing viewer · member access Original SGX announcement
Glenmark Pharmaceuticals Announces Exclusive Licensing Agreement with Seqirus General Announcement Filing viewer · member access Original SGX announcement
The US FDA Approves First Supplemental Abbreviated New Drug Application General Announcement Filing viewer · member access Original SGX announcement
GPL Announces Poster Presentations on GBR 1302 and GBR 1342 at the 2018 ASCO Annual Meeting General Announcement Filing viewer · member access Original SGX announcement
GPL Announces the First New Drug Application Submission for Ryaltris General Announcement Filing viewer · member access Original SGX announcement
Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride Tablets, 625 mg General Announcement Filing viewer · member access Original SGX announcement
GPL Announces Oral Presentation of New Data on GBR 830 General Announcement Filing viewer · member access Original SGX announcement
GPL Announces Oral Presentation of New Data on GBR 830 General Announcement Filing viewer · member access Original SGX announcement
Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Cream USP, 0.05 Per. General Announcement Filing viewer · member access Original SGX announcement
New and Updated Data on GPL GBR 830 General Announcement Filing viewer · member access Original SGX announcement
GPL receives ANDA approval for Clobetasol Propionate Topical Solution USP, 0.05 Per. General Announcement Filing viewer · member access Original SGX announcement
Exclusive Collaboration Agreement with SCD Pharmaceuticals, South Korea General Announcement Filing viewer · member access Original SGX announcement
New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody General Announcement Filing viewer · member access Original SGX announcement
Top Line Results from Phase 3 Safety Study Evaluating Ryaltris General Announcement Filing viewer · member access Original SGX announcement
Notification to Bondholders regarding the Fixed Exchange Rate General Announcement Filing viewer · member access Original SGX announcement
Notification to Bondholders regarding the initial Conversion Price General Announcement Filing viewer · member access Original SGX announcement
Glenmark Pharmaceuticals receives ANDA approval for Desonide Ointment, 0.05% General Announcement Filing viewer · member access Original SGX announcement
ANDA approval for Propafenone Hydrochloride Extended-Release Capsules USP 225 mg, 325 mg, and 425 mg General Announcement Filing viewer · member access Original SGX announcement
Glenmark Pharmaceuticals receives ANDA approval for Triamcinolone Acetonide Ointment USP, 0.1% General Announcement Filing viewer · member access Original SGX announcement
Glenmark Pharmaceuticals Reports Positive Data in a Phase 2a Study of GBR 830 General Announcement Filing viewer · member access Original SGX announcement
Employee Stock Options Scheme, 2016 General Announcement Filing viewer · member access Original SGX announcement
First Quarter Results Financial Statements and Related Announcement Filing viewer · member access Original SGX announcement
Glenmark Pharmaceuticals receives ANDA approval for Desonide Cream, 0.05% General Announcement Filing viewer · member access Original SGX announcement
MHRA, UK approval for Maloff Protect, anti-malarial medication as a Pharmacy license in the UK General Announcement Filing viewer · member access Original SGX announcement
:- Glenmark receives ANDA approval for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg General Announcement Filing viewer · member access Original SGX announcement